Skip to main content


Log in

Characterization of a neutralizing anti-human galectin-1 monoclonal antibody with angioregulatory and immunomodulatory activities

  • Letter
  • Published:
Angiogenesis Aims and scope Submit manuscript


Galectins, a family of highly conserved β-galactoside-binding proteins, control tumor progression by modulating different hallmarks of cancer. Galectin-1 (Gal-1), a proto-type member of this family, plays essential roles in tumor angiogenesis and immunosuppression by cross-linking glycosylated receptors on the surface of endothelial and immune cells. Targeted disruption of Gal-1 suppresses tumor growth by counteracting aberrant angiogenesis and reinforcing antitumor immunity in several experimental settings. Given the multiple therapeutic benefits associated with Gal-1 blockade, several Gal-1 inhibitors, including glycan-based competitors, antagonistic peptides, aptamers and neutralizing monoclonal antibodies, have been designed and evaluated in pre-clinical tumor models. Here we report the biochemical and functional characterization of a newly developed neutralizing anti-human Gal-1 monoclonal antibody (Gal-1-mAb3), which specifically recognizes a unique epitope in Gal-1 protein and exerts both angioregulatory and immunomodulatory activities. Blockade of Gal-1 function using Gal-1-mAb3, might be relevant not only in cancer but also in other pathologic conditions characterized by aberrant angiogenesis and uncontrolled immunosuppression.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2

Data availability

All data are available in the text and supplementary material.


  1. Girotti MR, Salatino M, Dalotto-Moreno T, Rabinovich GA (2020) Sweetening the hallmarks of cancer: galectins as multifunctional mediators of tumor progression. J Exp Med 217(2):e20182041.

    Article  CAS  PubMed  Google Scholar 

  2. Thijssen VL, Postel R, Brandwijk RJ et al (2006) Galectin-1 is essential in tumor angiogenesis and is a target for antiangiogenesis therapy. Proc Natl Acad Sci USA 103(43):15975–15980.

    Article  CAS  PubMed  Google Scholar 

  3. Thijssen VL, Barkan B, Shoji H et al (2010) Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70(15):6216–6224.

    Article  CAS  PubMed  Google Scholar 

  4. Croci DO, Salatino M, Rubinstein N et al (2012) Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi’s sarcoma. J Exp Med 209(11):1985–2000.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Hsieh SH, Ying NW, Wu MH et al (2008) Galectin-1, a novel ligand of neuropilin-1, activates VEGFR-2 signaling and modulates the migration of vascular endothelial cells. Oncogene 27(26):3746–3753.

    Article  CAS  PubMed  Google Scholar 

  6. Croci DO, Cerliani JP, Dalotto-Moreno T et al (2014) Glycosylation-dependent lectin-receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156(4):744–758.

    Article  CAS  PubMed  Google Scholar 

  7. Rubinstein N, Alvarez M, Zwirner NW et al (2004) Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5(3):241–251.

    Article  CAS  PubMed  Google Scholar 

  8. Toscano MA, Bianco GA, Ilarregui JM et al (2007) Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8(8):825–834.

    Article  CAS  PubMed  Google Scholar 

  9. Stowell SR, Qian Y, Karmakar S et al (2008) Differential roles of galectin-1 and galectin-3 in regulating leukocyte viability and cytokine secretion. J Immunol 180(5):3091–3102.

    Article  CAS  PubMed  Google Scholar 

  10. Ilarregui JM, Croci DO, Bianco GA et al (2009) Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10(9):981–991.

    Article  CAS  PubMed  Google Scholar 

  11. Dalotto-Moreno T, Croci DO, Cerliani JP et al (2013) Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 73(3):1107–1117.

    Article  CAS  PubMed  Google Scholar 

  12. Orozco CA, Martinez-Bosch N, Guerrero PE et al (2018) Targeting galectin-1 inhibits pancreatic cancer progression by modulating tumor-stroma crosstalk. Proc Natl Acad Sci USA 115(16):E3769–E3778.

    Article  CAS  PubMed  Google Scholar 

  13. Nambiar DK, Aguilera T, Cao H et al (2019) Galectin-1-driven T cell exclusion in the tumor endothelium promotes immunotherapy resistance. J Clin Invest 129(12):5553–5567.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  14. Navarro P, Martínez-Bosch N, Blidner AG, Rabinovich GA (2020) Impact of galectins in resistance to anticancer therapies. Clin Cancer Res.

    Article  PubMed  Google Scholar 

  15. Tejler J, Tullberg E, Frejd T et al (2006) Synthesis of multivalent lactose derivatives by 1, 3-dipolar cycloadditions: selective galectin-1 inhibition. Carbohydr Res 341(10):1353–1362.

    Article  CAS  PubMed  Google Scholar 

  16. Tsai YT, Liang CH, Yu JH et al (2019) A DNA aptamer targeting galectin-1 as a novel immunotherapeutic strategy for for lung cancer. Mol Ther Nucleic Acids 18:991–998.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Ouyang J, Juszczynski P, Rodig SJ et al (2011) Viral induction and targeted inhibition of galectin-1 in EBV + posttransplant lymphoproliferative disorders. Blood 117(16):4315–4322.

    Article  CAS  PubMed  Google Scholar 

  18. van Beijnum JR, Thijssen VL, Läppchen T et al (2016) A key role for galectin-1 in sprouting angiogenesis revealed by novel rationally designed antibodies. Int J Cancer 139(4):824–835.

    Article  CAS  PubMed  Google Scholar 

Download references


We thank R.M. Morales and G. Suárez for support in animal care and M. Fernández and E. Malchiodi (IDEHU; CONICET) for support in SPR assays.


This work was supported by Grants from Agencia Nacional de Promoción Científica y Tecnológica (PICT 2017-0494 to G.A.R. and PICT 2016-0205 to D.O.C.), CONICET (Fondo de Promoción Tecnológica R3449 to G.A.R.) as well as Bunge & Born and Sales Foundations (to G.A.R.)

Author information

Authors and Affiliations


Corresponding authors

Correspondence to Juan M. Pérez Sáez or Gabriel A. Rabinovich.

Ethics declarations

Ethics approval

All experimental procedures were approved by the Institutional Animal Care and Use Committee at the Institute of Biology and Experimental Medicine (IBYME, CONICET).

Conflict of interest

The authors declare no potential conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Electronic supplementary material 1 (PDF 4137 kb)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Pérez Sáez, J.M., Hockl, P.F., Cagnoni, A.J. et al. Characterization of a neutralizing anti-human galectin-1 monoclonal antibody with angioregulatory and immunomodulatory activities. Angiogenesis 24, 1–5 (2021).

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: